| NASDAQ (usa) |
|
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
| DAX (german) |
|
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Sanofi (MI: SANF)
SANF Technical Analysis
2
| As on 7th Mar 2024 SANF STOCK Price closed @ 87.89 and we RECOMMEND Sell for LONG-TERM with Stoploss of 90.91 & Strong Buy for SHORT-TERM with Stoploss of 82.07 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SANFSTOCK Price
| Open | 87.53 | Change | Price | % |
| High | 88.24 | 1 Day | 0.82 | 0.94 |
| Low | 87.53 | 1 Week | -1.03 | -1.16 |
| Close | 87.89 | 1 Month | -3.82 | -4.17 |
| Volume | 324 | 1 Year | 7.69 | 9.59 |
| 52 Week High 104.08 | 52 Week Low 77.64 | ||||
MI Italy Most Active Stocks
| TIT | 0.48 | -2.04% |
| TITR | 0.54 | -1.82% |
| ISP | 5.58 | -0.53% |
| SPM | 2.21 | 0.00% |
| BMPS | 7.42 | -2.37% |
| BPE | 10.31 | -0.48% |
| ENEL | 8.89 | -0.56% |
| NEXI | 3.99 | -2.92% |
| CPR | 5.65 | -5.36% |
| STLA | 15.58 | 0.45% |
MI Italy Top Gainers Stocks
MI Italy Top Losers Stocks
| SANF Daily Charts |
SANF Intraday Charts |
Whats New @ Bazaartrend |
SANF Free Analysis |
|
|
SANF Important Levels Intraday
| RESISTANCE | 89.26 |
| RESISTANCE | 88.82 |
| RESISTANCE | 88.55 |
| RESISTANCE | 88.28 |
| SUPPORT | 87.50 |
| SUPPORT | 87.23 |
| SUPPORT | 86.96 |
| SUPPORT | 86.52 |
SANF Forecast November 2025
| 4th UP Forecast | 98.1 |
| 3rd UP Forecast | 94.83 |
| 2nd UP Forecast | 92.8 |
| 1st UP Forecast | 90.78 |
| 1st DOWN Forecast | 85 |
| 2nd DOWN Forecast | 82.98 |
| 3rd DOWN Forecast | 80.95 |
| 4th DOWN Forecast | 77.68 |
SANF Weekly Forecast
| 4th UP Forecast | 94.62 |
| 3rd UP Forecast | 92.46 |
| 2nd UP Forecast | 91.13 |
| 1st UP Forecast | 89.79 |
| 1st DOWN Forecast | 85.99 |
| 2nd DOWN Forecast | 84.65 |
| 3rd DOWN Forecast | 83.32 |
| 4th DOWN Forecast | 81.16 |
SANF Forecast2025
| 4th UP Forecast | 141.75 |
| 3rd UP Forecast | 124.48 |
| 2nd UP Forecast | 113.8 |
| 1st UP Forecast | 103.12 |
| 1st DOWN Forecast | 72.66 |
| 2nd DOWN Forecast | 61.98 |
| 3rd DOWN Forecast | 51.3 |
| 4th DOWN Forecast | 34.03 |
Sanofi ( MI Italy Symbol : SANF )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SANF Other Details
| Segment | EQ | |
| Market Capital | 107509596160.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-General | |
| Offical website | > echo $website ; ?> | |
SANF Address
![]() |
||
SANF Latest News
SANF Business Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France. Address: 54, Rue La BoEtie, Paris, France, 75008
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service

